Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.39 USD | -0.45% | -3.30% | -44.99% |
Jun. 18 | Transcript : Alector, Inc. - Special Call | |
Jun. 10 | Transcript : Alector, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 01:20 PM |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-44.74% | 425M | C- | ||
+15.58% | 121B | B+ | ||
+16.60% | 110B | B+ | ||
+18.54% | 25.98B | B | ||
-24.33% | 19.27B | B+ | ||
-18.35% | 15.99B | A- | ||
-17.95% | 15.66B | B | ||
-48.32% | 14.5B | A- | ||
+58.78% | 14.47B | C+ | ||
+4.91% | 13.91B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALEC Stock
- Ratings Alector, Inc.